© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Predicting Resistance or Response to Chemotherapy by Proton Magnetic Resonance Spectroscopy in Neuroblastoma
Affiliations of authors: Childhood Cancer Research Unit, Department of Woman and Child Health, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden (ML, PK); MR-Centre, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden (CS); Astra Zeneca R & D, Södertälje, Sweden (CS); Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden (JJ, AG)
Correspondence to: Magnus Lindskog, Childhood Cancer Research Unit, Q6:05, Astrid Lindgren Children’s Hospital, Karolinska Hospital, S-171 76 Stockholm, Sweden (e-mail: magnus.lindskog{at}kbh.ki.se)
Background: We previously showed that proton magnetic resonance spectroscopy (1H-MRS) enables estimation of neuroblastoma tumor viability. Here we investigated if 1H-MRS can predict response or resistance to chemotherapy in neuroblastoma. Methods: Neuroblastoma cell lines with various drug sensitivities were treated with cytotoxic drugs (cisplatin, etoposide, and irinotecan) and examined by 1H-MRS. Viability was assessed by trypan blue staining and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. Nude rats carrying drug-sensitive or drug-resistant neuroblastoma xenografts were treated for 4 days with irinotecan (n = 11) or saline (n = 11) and were examined with 1H-MRS at 4.7 T before and during treatment. The Wilcoxon matched-pairs test was used to test statistical significance of difference within treatment groups. Independent groups were compared using the Mann–Whitney U test. Correlation was assessed with Spearman’s rank correlation. All statistical tests were two-sided. Results: Cytotoxic drug treatment of drug-sensitive SH-SY5Y neuroblastoma cells resulted in increased methylene and polyunsaturated fatty acid resonances and decreased choline resonance. The methylene/choline ratio correlated with cell death (rs = .94, P<.001) and was increased in cisplatin-treated drug-sensitive (SH-SY5Y, IMR-32) but not drug-resistant [SK-N-BE(2), SK-N-FI, SK-N-AS] cell lines. No changes were observed in SK-N-BE(2) cells treated with irinotecan or cisplatin, whereas circumvention of the resistance by arsenic trioxide treatment led to lipid accumulation and choline depletion. Irinotecan therapy of rats carrying drug-sensitive xenografts caused the methylene/choline ratio of tumors to increase eightfold after 3 days (95% confidence interval [CI] = fivefold to 12-fold; P = .005 compared with pretreatment spectra at day 0) and caused tumors to regress statistically significantly on day 10 compared with pretreatment volume on day 0 (difference = –60%, 95% CI = –12% to -100%, n = 6; P = .012). The methylene/choline ratio of nonregressing drug-resistant xenografts was unaffected. No differences were observed after saline treatment. Conclusions: Response or resistance to chemotherapy is accurately predicted by 1H-MRS in experimental neuroblastoma models in vivo.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. M. Claudino, A. Quattrone, L. Biganzoli, M. Pestrin, I. Bertini, and A. Di Leo Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications J. Clin. Oncol., July 1, 2007; 25(19): 2840 - 2846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Johnsen, M. Lindskog, F. Ponthan, I. Pettersen, L. Elfman, A. Orrego, B. Sveinbjornsson, and P. Kogner Cyclooxygenase-2 Is Expressed in Neuroblastoma, and Nonsteroidal Anti-Inflammatory Drugs Induce Apoptosis and Inhibit Tumor Growth In vivo Cancer Res., October 15, 2004; 64(20): 7210 - 7215. [Abstract] [Full Text] [PDF]
|
|